But here is the trade off. Companion diagnostics will ensure closer scrutiny of efficacy and cost benefit by regulators, users and health payers but also will end any revenue generating speculative prescribing.
Companion diagnostics are here to stay. It is unthinkable that, in time, biologic drugs will be approved without them. This compelling market study provides a complete appraisal of the competitive, regulatory and product issues shaping companion diagnostics.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/es256532-complete-guide-companion-diagnostics-market.html
Global Cancer Biomarkers Market 2012-2016
The global cancer biomarkers market is forecast to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Cancer Biomarkers market has also been witnessing the trend of the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.
The key vendors dominating the global cancer biomarkers market space are Abbott Laboratories, Affymetrix, Inc., Agilent Technologies Inc., Gen-Probe Inc., Hologic, Inc., and Roche Diagnostics Corp.
Additional vendors mentioned in the report include: Agendia BV, Ambrilia Biopharma, Astellas Pharma US Inc., Morphotek, Inc., Gen-Probe, Inc., Veridex LLC, Morphotek, Inc
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved